本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：300434 证券简称：金石亚药 公告编号：2023-015 四川金石亚洲医药股份有限公司 关于召开 2022 年度网上业绩说明会的公告 四川金石亚洲医药股份有限公司（以下简称"公司"）将于 2023 年 5 月 19 日（星期五）15:00-17:00 在全景网举行 2022 年度网上业绩说明会。本次业绩说 明会将采用网络远程方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长、总经理魏宝康先生、董事、副总经 理、董事会秘书林强先生、财务总监王庆国先生、独立董事汪立荔女士。 特此公告。 四川金石亚洲医药股份有限公司 董 事 会 二〇二三年五月十六日 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度网上业绩说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 18 日（星期四）12:00 前访问 http://ir.p5w.net/zj/，或扫描下方二 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 419,787,729.70, representing a 33.27% increase compared to CNY 314,985,330.83 in the same period last year[4]. - Net profit attributable to shareholders for Q1 2023 was CNY 143,460,482.45, a significant increase of 115.49% from CNY 66,575,529.07 in the previous year[4]. - The net profit after deducting non-recurring gains and losses was CNY 139,339,589.63, up 120.19% from CNY 63,281,312.18 year-on-year[4]. - The basic earnings per share for Q1 2023 was CNY 0.3571, reflecting a 110.06% increase from CNY 0.17 in the same quarter last year[4]. - Total operating revenue for Q1 2023 reached CNY 419,787,729.70, a significant increase from CNY 314,985,330.83 in the same period last year, representing a growth of approximately 33.3%[15]. - The company reported an operating profit of CNY 184,249,348.46, compared to CNY 80,200,301.74 in the previous year, reflecting an increase of approximately 129.1%[15]. - The total comprehensive income for Q1 2023 was CNY 142.50 million, compared to CNY 65.60 million in Q1 2022, reflecting an increase of 117.5%[16]. Assets and Liabilities - The company's total assets at the end of Q1 2023 were CNY 3,040,493,261.49, a slight decrease of 0.63% from CNY 3,059,913,477.69 at the end of the previous year[4]. - The total current assets at the end of the reporting period were CNY 1,245,227,814.53, a slight decrease from CNY 1,261,062,751.33 at the beginning of the year, down by approximately 1.3%[12]. - The total liabilities decreased to CNY 594,640,857.64 from CNY 756,559,066.03, a reduction of about 21.4%[13]. - The total equity attributable to shareholders increased to CNY 2,417,690,284.28 from CNY 2,274,229,801.83, reflecting a growth of approximately 6.3%[13]. - The cash and cash equivalents decreased to CNY 386,869,329.36 from CNY 440,308,115.39, a decline of about 12.1%[12]. - Inventory levels rose to CNY 216,145,442.93 from CNY 197,369,370.03, an increase of approximately 9.5%[12]. Cash Flow - The net cash flow from operating activities for Q1 2023 was negative CNY 57,691,400.00, a decline of 475.91% compared to a positive cash flow of CNY 15,346,997.87 in the same period last year[4]. - Cash inflows from operating activities totaled CNY 360.72 million, compared to CNY 264.45 million in Q1 2022, indicating a rise of 36.4%[19]. - The total cash outflow from investing activities was CNY 4.65 million, compared to CNY 45.71 million in Q1 2022, showing a decrease of 89.8%[19]. - The net cash flow from financing activities was CNY 7.37 million, with no cash inflow reported in Q1 2022[20]. Market and Operational Performance - The company experienced a significant increase in market demand for its main products, leading to improved operational performance[7]. - The company has implemented production mechanism adjustments and optimized production processes to significantly increase output in response to market demand[7]. - Research and development expenses increased to CNY 17,587,226.51 from CNY 12,937,760.46, marking a rise of about 36.3%[15]. Foreign Exchange and Non-Recurring Items - The company reported non-recurring gains totaling CNY 4,120,892.82 for the quarter, after accounting for tax effects[5]. - The company experienced a foreign exchange loss of CNY -272,954.05 in Q1 2023, compared to a loss of CNY -48,275.32 in Q1 2022[20].

Financial Performance - The company's operating revenue for 2022 was ¥1,242,603,080.88, representing a 17.95% increase compared to ¥1,053,504,604.27 in 2021[27]. - The net profit attributable to shareholders for 2022 was ¥218,786,883.71, a significant increase of 229.10% from ¥66,480,785.93 in 2021[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥195,753,270.89, up 244.90% from ¥56,756,082.55 in 2021[27]. - The net cash flow from operating activities for 2022 was ¥323,041,794.10, an increase of 136.84% compared to ¥136,395,575.72 in 2021[27]. - The total assets at the end of 2022 amounted to ¥3,059,913,477.69, reflecting a 10.54% increase from ¥2,768,127,717.25 at the end of 2021[27]. - The net assets attributable to shareholders at the end of 2022 were ¥2,274,229,801.83, a 9.14% increase from ¥2,083,751,254.61 at the end of 2021[27]. - The basic earnings per share for 2022 was ¥0.54, representing a 217.65% increase from ¥0.17 in 2021[27]. - The weighted average return on equity for 2022 was 10.06%, up from 3.24% in 2021, indicating improved profitability[27]. - The company reported a net profit of ¥111,778,590.21 in Q4 2022, contributing significantly to the annual performance[29]. - The company reported a net profit of approximately 66.48 million yuan for the 2021 fiscal year, with a negative retained earnings balance of approximately -197.58 million yuan[141]. - The company reported a net profit margin of 12% for 2022, reflecting effective cost management and operational efficiency improvements[172]. Product Portfolio and Market Position - The company reported a significant reliance on its main products, with the sales revenue from the "Kuaike" cold medicine series accounting for a high percentage of total revenue and gross profit[5]. - The company has over 90 drug production approval numbers and 6 health food production approval numbers, indicating a strong product portfolio[5]. - The company's flagship products, "Kuaike" and "Xiaokuaike," have maintained leading positions in the OTC cold medicine market for three consecutive years[42]. - The company has developed a product matrix for its "Kuaike" and "Xiaokuaike" brands, expanding from a single cold medicine to a diversified over-the-counter (OTC) drug brand with multiple varieties[44]. - The "Kuaike" series products, including "Kuaike" compound acetaminophen and "Xiaokuaike" pediatric acetaminophen, have become well-known brands in China, achieving significant market recognition and competitive advantages[44]. - The company is actively developing products in respiratory, digestive, orthopedic, and pediatric areas, enhancing its competitive edge in the pharmaceutical sector[43]. - The company is enhancing its prescription drug offerings, including innovative Western medicines such as "Kuaike Xilin" and "Amoxicillin Clavulanate Potassium Dispersible Tablets," to expand its sales scale[45]. - The company is investing in the development of high-end raw materials, particularly calcium carbonate, to strengthen its market position in the calcium supplement category[45]. - The company is actively expanding its health food product line and has established a B2C e-commerce platform, leveraging online channels to reduce distribution costs and inventory pressure compared to traditional health food manufacturers[44]. Competition and Market Risks - The company faces risks from increasing competition in the cold medicine and health food markets, which may threaten its market share[4]. - The company anticipates ongoing price reductions in the pharmaceutical industry, which may negatively impact average profit margins and overall performance[7]. - The company acknowledges the potential impact of national procurement policies on pricing and market dynamics, which could affect its competitive position[6]. - The demand for cold medications has surged due to recent health policies and increased self-medication practices among consumers[39]. Research and Development - The company has a focus on developing new products, particularly in the calcium and mineral series, as part of its future growth strategy[6]. - The company is advancing multiple R&D projects, including a generic drug consistency evaluation project aimed at enhancing product competitiveness[67]. - Research and development (R&D) investment amounted to CNY 39,184,819.23, accounting for 3.15% of operating revenue[69]. - The company is investing 100 million CNY in R&D for new technologies aimed at enhancing product efficacy and safety[117]. - The company is investing heavily in R&D, allocating 200 million yuan, which is 16.67% of its total revenue, to develop new technologies and products[167]. Strategic Initiatives and Investments - The company is investing in projects such as the Jinxi raw material drug project and the subsidiary formulation workshop renovation project, which involve substantial capital expenditure[6]. - The company has established long-term stable partnerships with major suppliers to ensure raw material supply, although it remains vulnerable to price fluctuations and supply shortages due to external factors[5]. - The company is committed to becoming a trusted provider in the pharmaceutical health sector, focusing on quality, technology, and brand excellence[42]. - The company aims to enhance the promotion of existing products, particularly the Kuaike cold medicine matrix and the Kuaike children's medication series, targeting to develop star products within 2-3 years[90]. - The company is focusing on strategic upgrades and resource integration to enhance management efficiency and address operational bottlenecks encountered in 2023[90]. - The company plans to invest in and acquire traditional Chinese medicine production enterprises to strengthen its product pipeline[90]. - The company is exploring potential mergers and acquisitions to further strengthen its market position, with a focus on companies that complement its existing product lines[173]. Corporate Governance and Compliance - The company has implemented strict internal control standards for product quality, exceeding national standards, to mitigate risks associated with product quality control[6]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, aligning with legal regulations[104]. - The company has a board of directors consisting of 11 members, including 4 independent directors, ensuring compliance with legal and regulatory standards[101]. - The company has established a governance structure that complies with regulatory requirements, ensuring effective decision-making processes[99]. - The company has committed to maintaining independence from its controlling shareholders, ensuring no interference in its operational decisions[168]. Social Responsibility and Community Engagement - The company donated a total of ¥2,154,000 worth of products, including cold medicine, to frontline logistics personnel and local charities during the reporting period[158]. - The company actively participates in public welfare activities, contributing to local community development and maintaining good relations with government entities[157]. - The company has not reported any incidents of environmental pollution or violations of environmental protection laws during the reporting period[158]. - The company maintains a commitment to employee rights and welfare, providing comprehensive benefits including various types of insurance and paid leave[157]. Future Outlook - Future guidance suggests a projected revenue growth rate of approximately 15% for the upcoming fiscal year[112]. - The company has provided a revenue guidance of 1.5 billion CNY for the upcoming fiscal year, projecting a growth rate of 25%[117]. - The company aims to launch three new products in 2023, which are anticipated to generate approximately 500 million yuan in sales[169]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[170]. - The company is focused on market expansion and potential mergers and acquisitions to enhance its competitive position[198].

证券代码： 300434 证券简称：金石东方 编号：2015-01 四川金石东方新材料设备股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 长江证券 刘 军 | | | 人员姓名 | 西南证券 王立洲 | | | 时间 | 2015 年 8 月 27 | 日、 2015 年 8 月 28 日 | | 地点 | 公司会议室 | | | 上市公司接待人 | 副总经理、董事 姬昱川 | | | 员姓名 | 副总经理、董秘 林 强 | | | 投资者关系活动 | 一、基本情况介绍； | | | 主要内容介绍 ...

证券代码： 300434 证券简称：金石东方 编号：2015-02 四川金石东方新材料设备股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 华泰证券 秦 瑞 | | | 人员姓名 | 东方证券 佘炜超 | | | | 国联安基金 刘佃贵 | | | 时间 | 2015 年 11 月 10 | 日、 2015 年 11 月 11 日 | | 地点 | 公司会议室 | | | 上市公司接待人 | 副总经理、董秘：林 强 | | | 员姓名 | 证券事务代表： 张天涯 | | | 投资者关系活动 | ...

证券代码： 300434 证券简称：金石东方 编号：2015-03 四川金石东方新材料设备股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 长江证券 万广博 | | | 人员姓名 | 长江证券 姚 远 | | | 时间 | 2015 年 12 月 11 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人 | 副总经理、董秘：林 强 | | | 员姓名 | 证券事务代表： 张天涯 | | | 投资者关系活动 | 一、基本情况介绍； | | | 主要内容介绍 | 2015 | 年前三季 ...